fashion -WSS

fashion

author：hotspot 2025-09-27 23:00:24 - browse：193

Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the industry says will warp how cancer drugs are developed. On Wednesday, AstraZeneca CEO Pascal Soriot proposed a new solution.

“What we were asking — and are asking now — is a very simple fix,” said Soriot at the STAT Future Summit, saying that “the impact on health care costs would be very marginal.”

The problem, executives say, is that companies developing cancer drugs today generally start small and then go big. They seek approval first in a small setting, such as patients who have exhausted all other therapies, where it’s easiest in terms of trial size and length to show a benefit. Then they go into larger settings, such as newly diagnosed patients, where studies take longer but the revenue potential is much higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： David Sabatini, ex

WSS

Average age of first period drops to 11.9 years, study shows

FDA has safety concerns on CRISPR

Why Sanofi got shellacked over its spinoff

Startling documents reveal new facets of Sacklers' opioid empire

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

WHO may add ‘noma' to its list of neglected tropical diseases

entertainment

fashion

entertainment

In age of alternative facts, a scholarly course on calling out crap

Emergency medicine has repudiated 'excited delirium.' Now what?

Psychedelics group wrestles with new pharma identity

Meta's Zuckerberg and Chan on track to put $50 billion into science

Walensky prepares to leave CDC — and Congress — behind

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Dobbs anniversary: the lost opportunity of abortion as health care

Startling documents reveal new facets of Sacklers' opioid empire

Alkermes shareholders re

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

entertainment

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Average age of first period drops to 11.9 years, study shows

Average age of first period drops to 11.9 years, study shows

Testing for cancer recurrence creates a new limbo for patients

The FDA weighs the risks of candy

Eli Lilly to pay $200M for Beam’s stake in gene

hotspot

explore

explore

Wikipedia